Trials / Terminated
TerminatedNCT01525069
Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma
Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This pilot clinical trial studies the safety and effectiveness of continuous hepatic arterial infusion (HAI) of floxuridine (FUDR) alone or in combination with other chemotherapeutic drugs in treating patients with locally advanced cholangiocarcinoma that cannot be removed by surgery. HAI is a method to deliver higher concentrations of FUDR more directly to liver tumors and reduces side effects. HAI alone or in combination with oxaliplatin and/or gemcitabine may significantly improve clinical outcomes of patients with locally advanced cholangiocarcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Floxuridine | |
| DRUG | Dexamethasone | |
| DRUG | Gemcitabine | |
| DRUG | Oxaliplatin |
Timeline
- Start date
- 2012-04-03
- Primary completion
- 2018-08-08
- Completion
- 2022-08-02
- First posted
- 2012-02-02
- Last updated
- 2022-08-10
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01525069. Inclusion in this directory is not an endorsement.